{"symbol":"REGN","fiscalQuarter":"Q3-2014","reportDate":"2014-11-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2014","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 5.79%","keyNumbers":[{"metric":"EPS","actual":"$2.52","expected":"N/A","surprise":"+20.00%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They noted ongoing investments in research and development.","There was an emphasis on maintaining a robust pipeline."],"summary":"Overall, management expressed confidence in the company's future growth. They emphasized the importance of their product pipeline and ongoing R&D efforts."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 5.79% on the day, likely due to the lack of revenue details and forward guidance. Investors may be concerned about future performance without clearer expectations from management.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2014 earnings: EPS beat, stock down 5.79%. Full breakdown of results and management commentary."}}